Quick answer: The FDA’s Pharmacy Compounding Advisory Committee met July 23 and 24, 2026 and recommended six of seven peptides for the 503A Bulks List: BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon. Emideltide, also called DSIP, was rejected. Every vote was close, and the committee went against its own FDA staff’s written recommendation on all six approvals. None of it is binding. Nothing became legal to compound. The FDA still has to run a formal rulemaking process, which realistically extends into 2027.
What actually happened in the room
Fourteen committee members met at the FDA’s White Oak campus in Silver Spring, Maryland, working through seven peptides one at a time, with separate votes on the free-base and acetate forms of each.
Day one covered four compounds. BPC-157, KPV, and TB-500 each passed 8-6 with one abstention, and MOTS-c passed 7-5 with two abstentions. Day two covered three more. Semax and Epitalon both passed, and DSIP, also called emideltide, was rejected by a single vote.
The most striking detail is not the outcome but the disagreement behind it. The FDA’s own scientists had recommended against all seven compounds in the agency’s briefing documents. The committee overruled staff on six of them. The committee agreed with FDA staff on only one compound: emideltide.
That is unusual. Advisory committees frequently align with staff analysis, and a fourteen-member panel splitting 8-6 six separate times against its own agency’s written position tells you the evidence base is genuinely contested rather than settled in either direction.
The part almost every headline got wrong
Within hours of the vote, the internet filled with variations of “peptides are legal again.” They are not, and the distance between a committee recommendation and legal access is larger than most coverage suggested.
The votes do not make these peptides FDA-approved drugs. They represent a recommendation that the compounds be added to a list of substances compounding pharmacies are permitted to prepare for patients with a prescription. The FDA is not bound by the panel’s recommendations, and any change would require a formal rulemaking process.
Here is the sequence that still has to run. The FDA reviews the recommendation and decides whether to initiate formal rulemaking. If it proceeds, it publishes a Notice of Proposed Rulemaking in the Federal Register, opens a public comment period, reviews those comments, and publishes a Final Rule adding the substances to the 503A Bulks List. This process typically takes twelve months or more after a committee recommendation.
The votes represent an important step forward, but they do not immediately change regulatory status or make these substances available through 503A compounding pharmacies. Or put in the bluntest available terms: the practical status of BPC-157, TB-500, KPV, MOTS-c, Semax, and Epitalon is unchanged today. Compounding pharmacies still cannot prepare them.
If a clinic tells you otherwise this month, they are either not following the process or they are counting on you not to.
Three legal events, constantly confused
There are three distinct milestones here, and treating them as one is where nearly all the confusion originates.
Removal from Category 2. Happened in April 2026 for twelve peptides. Category 2 was the FDA’s designation for substances presenting potential safety concerns, effectively a do-not-compound instruction. Coming off that list removes a prohibition. It does not grant permission.
A PCAC recommendation. Happened last week for six peptides. An expert panel telling the FDA what it thinks the agency should do. Advisory only.
Placement on the 503A Bulks List. Has not happened. This is the affirmative list that actually authorizes a licensed pharmacy to compound a substance against a prescription. It requires the FDA to complete rulemaking.
Only the third one changes what your pharmacy can legally make. The first two are steps toward it.
A detail worth noticing: these were nominated for conditions
Something largely absent from the coverage is that each peptide was evaluated for a specific medical indication rather than for general wellness use. BPC-157 was nominated for ulcerative colitis. MOTS-c was nominated for obesity and osteoporosis.
That framing matters. Even in the most favorable scenario where the FDA completes rulemaking and adds these to the list, placement is tied to the nominated context. It is not a blanket authorization to prescribe a compound for whatever a patient read about online.
What comes next, and when
The FDA will review the votes, the meeting record, public comments, and its internal evaluations. At a date not yet announced, it may publish an interim policy update, a proposed rule, a final rule, or another formal decision. Before the end of February 2027, the agency expects another PCAC consultation involving GHK-Cu for non-injectable routes.
A second PCAC meeting covering an additional five peptides is expected around February 2027.
So the realistic timeline for any of this becoming prescribable runs well into next year, assuming the FDA acts favorably at all — and having just been overruled by its own advisory committee, the agency’s response is genuinely difficult to predict.
Our position at Brandon Medical Center
We are not changing what we offer based on a non-binding vote, and we would be skeptical of any clinic that did.
What we will do is keep watching the rulemaking docket and tell patients plainly where things stand. For the goals most people bring to us when they ask about peptides — fatigue, body composition, recovery, metabolic health — there are FDA-approved medications available today with substantially better evidence behind them. That remains the right first conversation, and it will still be the right first conversation next year.
If you want a straight read on where peptide therapy sits and whether it fits your situation, call Brandon Medical Center at (813) 502-6430 or request an appointment online. We are at 122 S Moon Ave, Brandon, FL 33511.
Regulatory information reflects publicly available reporting as of July 30, 2026 and is subject to change. This article is general information, not medical advice.
